Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD
Chronic obstructive pulmonary disease (COPD) is a condition characterized by airway obstruction. Patients with COPD experience significant shortness of breath on exertion. The mechanisms responsible for shortness of breath on exertion are well understood in moderate and severe COPD, but, are poorly understood in mild C
| Condition(s) | Chronic Obstructive Pulmonary Disease |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | Chronic obstructive pulmonary disease (COPD) is a condition characterized by airway obstruction. Patients with COPD experience significant shortness of breath on exertion. The mechanisms responsible for shortness of breath on exertion are well understood in moderate and severe COPD, but, are poorly understood in mild COPD where symptoms appear disproportionate to the degree of airway obstruction. Mild COPD patients show an exaggerated breathing response to exercise, determined by the breathing response to carbon dioxide production (V̇E/V̇CO2). Recent work suggests that the increased V̇E/V̇CO2 during exercise in mild COPD is secondary to increased deadspace (i.e. lung regions with ventilation but no perfusion) and/or ventilation/perfusion (V̇A/Q) inequality (poor matching of ventilation to |
| Who can participate | Inclusion Criteria: Participants will have COPD as defined as: 1. Post bronchodilator Forced Expiratory Volume in one second (FEV1) to Forced Vital Capacity (FVC) ratio (FEV1/FVC) below the lower limit of normal 2. FEV1 \>30% of predicted (lower limit of GOLD severe COPD classification) COPD Free Controls will have: 1. No diagnosis of COPD 2. Post bronchodilator Forced Expiratory Volume in one second (FEV1) to Forced Vital Capacity (FVC) ratio (FEV1/FVC) above the lower limit of normal 3. FEV1 \>80% of predicted Exclusion Criteria: 1. Absolute contraindication to exercise testing or an orthopedic condition that may limit exercise testing. 2. Pre-existing cardiac conditions (heart failure, congenital heart defect, valvular disease) that may limit exercise testing 3. A diagnosis of pulmonary |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | University of Alberta |
| Locations | Edmonton, Alberta, Canada |
| Start date | 2022-03-01 |
| NCT ID | NCT05061368 |
| Official listing | https://clinicaltrials.gov/study/NCT05061368 |